hVIVO CEO sees strong H2 2026 revenue outlook as development platform expands - ICYMI Proactive uses images sourced from ShutterstockThis week hVIVO PLC (AIM:HVO) chief executive Mo Khan joined Proactive to talk about how the clinical research company has more than doubled its order book as commercial momentum accelerates. Khan said the company has transformed into an integrated end-to-end clinical development provider, with growing demand reflected in a 45% year-on-year increase in inbound client proposals. It has been a very significant first half for hVIVO following the launch of our integrated end-to-end platform for early-stage clinical development under the hVIVO brand in April. The integrated platform allows us to provide end-to-end clinical development, from consulting through human challenge trials, laboratory services and non-human challenge trials. The £65 million order book provides confidence and extends into 2027 and 2028.